Comparison of DNA and mRNA vaccines against cancer

Zohreh Jahanafrooz, Behzad Baradaran, Jafar Mosafer, Mahmoud Hashemzaei, Tayebeh Rezaei, Ahad Mokhtarzadeh, Michael R. Hamblin

Research output: Contribution to journalReview articlepeer-review

123 Citations (Scopus)

Abstract

Nucleic acid vaccines (NAVs) have recently been tested as a cancer therapy. DNA and mRNA vaccines deliver genetic information encoding tumor antigens (TAs) to the host, which then produces immune responses against cancer cells that express the TAs. Although NAVs are easy, safe, and simple to manufacture, they have not so far been considered viable alternatives to peptide vaccines. Choosing the right TAs, insufficient immunogenicity, and the immunosuppressive nature of cancer are some challenges to this approach. In this review, we discuss approaches that been used to improve the efficiency of anticancer NAVs.

Original languageEnglish
Pages (from-to)552-560
Number of pages9
JournalDrug Discovery Today
Volume25
Issue number3
DOIs
Publication statusPublished - Mar 2020

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Comparison of DNA and mRNA vaccines against cancer'. Together they form a unique fingerprint.

Cite this